Amrutanjan Health Care Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹135 Cr +14.4% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
AH

Amrutanjan Health Care Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Amrutanjan Health Care Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹141Cr
+14.6% YoY
+19.5% QoQ
Net profit
₹19Cr
0% YoY
+35.7% QoQ
Margin
18%
−1 pp YoY
+4 pp QoQ

Based on Amrutanjan Health Care Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹510
Market cap₹1.4K Cr
P/E23.0

The short version

Q3 FY26 Revenue from Operations: Rs. 141.03 Cr, up 14.90% YoY (Q3 FY25: Rs. 122.75 Cr). EBITDA for Q3 FY26: Rs. 34.12 crore, a 13.0% increase YoY (Q3 FY25: Rs. 30.22 crore) [Page 29].

From Amrutanjan Health Care Ltd's Q3 FY26 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q3 FY26 Revenue from Operations: Rs. 141.03 Cr, up 14.90% YoY (Q3 FY25: Rs. 122.75 Cr)
  • Gross Sales - OTC (Q3 FY26): Rs. 148.33 Cr, up 12.48% YoY (Q3 FY25: Rs. 131.87 Cr)
  • Net Sales - OTC (Q3 FY26): Rs. 137.22 Cr, up 16.43% YoY (Q3 FY25: Rs. 117.86 Cr)
  • Net Sales - Comfy (Q3 FY26): Rs. 36.68 Cr, up 22.55% YoY (Q3 FY25: Rs. 29.93 Cr)
  • Beverage Gross Sales (Q3 FY26): Rs. 3.64 Cr, down from Rs. 5.54 Cr in Q3 FY25
  • Q3 FY26 Profit Before Tax: Rs. 26.36 Cr (minimal growth YoY)

2 more points from Amrutanjan Health Care Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Amrutanjan Health Care Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

See what Amrutanjan Health Care Ltd said on capital expenditure plans — free account, 30 seconds.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Amrutanjan Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Amrutanjan Health Care Ltd said on order book & pipeline — free account, 30 seconds.

Amrutanjan Health Care Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Amrutanjan Health Care Ltd Q3 FY26 results — key figures

Amrutanjan Health Care Ltd Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue141123+14.6%118+19.5%
Operating profit (EBITDA)2523+8.7%17+47.1%
Operating margin18%19%-1 pp14%+4 pp
Profit before tax26260%19+36.8%
Net profit (PAT)19190%14+35.7%
EPS (₹)6.736.66+1.1%4.83+39.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹135 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Amrutanjan Health Care Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Amrutanjan Health Care Ltd Q3 FY26 results?

Q3 FY26 Revenue from Operations: Rs. 141.03 Cr, up 14.90% YoY (Q3 FY25: Rs. 122.75 Cr). EBITDA for Q3 FY26: Rs. 34.12 crore, a 13.0% increase YoY (Q3 FY25: Rs. 30.22 crore) [Page 29].

What is Amrutanjan Health Care Ltd share price analysis?

Amrutanjan Health Care Ltd currently shows a neutral. The stock trades at a P/E of 22.9 with a market cap of ₹1,428 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Amrutanjan Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.